Sign in
Active, not recruitingNo phase

Acute Normovolemic Hemodilution in High Risk Cardiac Surgery Patients.

Key facts

Who runs it
Università Vita-Salute San Raffaele
Where
Charlottesville and Oklahoma City, United StatesSee the 2 sitesAlso in 10 other countries, 30 sites
Trial code
Status
Active, not recruiting
People taking part
2,000 people, planned
Started
15 Apr 2019
Expected to end
Dec 2026
Type of study
Interventional, 2 groups
Treatments tested
  • Acute normovolemic hemodilution
  • Standard care
Record updated
8 May 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Signed informed consent
  • Any cardiac surgical intervention on CPB
  • Elective surgery

Who cannot take part

  • Emergency surgery
  • Unstable Coronary Artery Disease: Recent (< 6 weeks) myocardial infarction, unstable angina, severe (> 70%) left main coronary artery stenosis
  • Critical preoperative state (ventricular tachycardia or ventricular fibrillation or aborted sudden death, preoperative cardiac massage, preoperative ventilation before anesthetic room, hemodynamic instability, preoperative inotropes or IABP, preoperative severe acute renal failure (anuria or oliguria <10ml/hr.)
  • Medical decision (e.g.: planned pre-CPB ANH considered undeniable for ethical reasons or not applicable for safety issues)
  • Pregnancy
  • Unfeasibility to withdraw ≥ 650 ml without inducing hemodynamic instability
  • Unfeasibility to withdraw ≥ 650 ml without inducing pre-CPB anemia (Htc <30%)
  • Unfeasibility to withdraw ≥ 650 ml without inducing low Htc during CPB (Htc <24%)

Where in United States

Also in 10 other countries, 30 sites

  • University of VirginiaCharlottesville, United States
  • OUHSC - University of OklahomaOklahoma City, United States

About the trial

What the trial wants to find out

Transfusions are one of the most overused treatments in modern medicine, and saving blood is one important issue all around the world. Cardiac surgery makes up a large percentage of the overall blood components consumption in surgery.

Read full original descriptionShow less

Acute normovolemic hemo-dilution (ANH) is a well-known strategy which has been used for years without the support of high quality evidence based medicine to improve post-cardiopulmonary bypass coagulation and reduce red blood cells (RBC) transfusion. We designed a multicenter randomized controlled trial to investigate the effect of ANH in reducing the number of cardiac surgery patients receiving RBC transfusions during hospital stay. We will randomize 2000 patients to have sufficient power to demonstrate a 20% relative and 7% absolute risk reduction in the number of patients' RBC transfusion. If the results of the study will confirm our hypothesis, this will have a great impact on blood management in cardiac operating room.

The 2 groups in the trial

  • ANHTreatment being tested

    Best available treatments plus ANH, performed withdrawing a volume of blood before the CPB. The volume will be personalized for every patient, but it'll be at least 650ml.

    Treatment: Acute normovolemic hemodilution

  • Standard careOther group

    No ANH

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Acute Normovolemic Hemodilution in High-risk Cardiac Surgery Patients. A Multicentre Randomized Trial.
Record updated
8 May 2026